Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models

被引:9
|
作者
Wang, Li [1 ,2 ]
Zhang, Haiyan [3 ]
Guan, Lixun [1 ]
Zhao, Shasha [1 ]
Gu, Zhenyang [1 ]
Wei, Huaping [1 ]
Gao, Zhe [1 ]
Wang, Feiyan [1 ]
Yang, Nan [1 ]
Luo, Lan [1 ]
Li, Yonghui [1 ]
Wang, Lili [1 ]
Liu, Daihong [1 ]
Gao, Chunji [1 ]
机构
[1] Chinese Peoples Liberat Army PLA Gen Hosp, Dept Hematol, Beijing, Peoples R China
[2] 401 Hosp Chinese PLA, Laoshan Branch, Dept Hematol & Oncol, Qingdao, Peoples R China
[3] Linyi Peoples Hosp, Dept Hematol, Linyi, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
mesenchymal stem cells; graft-versus-host disease; hematopoietic stem cell transplantation; meta-analysis; animal experimentation; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; SUPPRESS LYMPHOCYTE-PROLIFERATION; REGULATORY T-CELLS; STROMAL CELLS; IMMUNOSUPPRESSIVE PROPERTIES; MOUSE MODEL; IN-VITRO; THERAPEUTIC-EFFICACY; PUBLICATION BIAS;
D O I
10.18632/oncotarget.11238
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A meta-analysis of animal models was conducted to evaluate the prophylactic effects of mesenchymal stem cells (MSCs) on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. A total of 50 studies involving 1848 animals were included. The pooled results showed that MSCs significantly reduced aGVHD-associated mortality (risk ratio = 0.70, 95% confidence interval 0.62 to 0.79, P = 2.73x10(-9)) and clinical scores (standardized mean difference = -3.60, 95% confidence interval -4.43 to -2.76, P = 3.61x10(-17)). In addition, MSCs conferred robust favorable prophylactic effects on aGVHD across recipient species, MSC doses, and administration times, but not MSC sources. Our meta-analysis showed that MSCs significantly prevented mortality and alleviated the clinical manifestations of aGVHD in animal models. These data support further clinical trials aimed at evaluating the efficacy of using MSCs to prevent aGVHD.
引用
收藏
页码:61764 / 61774
页数:11
相关论文
共 50 条
  • [41] Gut decontamination during allogeneic hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease
    Lars K. Gjærde
    Mette Schmidt
    Henrik Sengeløv
    Bone Marrow Transplantation, 2018, 53 : 1061 - 1064
  • [42] Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Weissinger, Eva M.
    Schiffer, Eric
    Hertenstein, Bernd
    Ferrara, James L.
    Holler, Ernst
    Stadler, Michael
    Kolb, Hans-Jochem
    Zander, Axel
    Zurbig, Petra
    Kellmann, Markus
    Ganser, Arnold
    BLOOD, 2007, 109 (12) : 5511 - 5519
  • [43] Incidence and risk factors of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation in childhood
    Prete, A
    Rondelli, R
    Dini, G
    Giorgiani, G
    Messina, C
    Fagioli, F
    Uderzo, C
    Locatelli, F
    Pession, A
    BONE MARROW TRANSPLANTATION, 2003, 31 : S26 - S26
  • [44] Association Between MDSCs and Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
    Liu, Qifa, Sr.
    Ling, Yiwen
    Fan, Zhiping
    Zhang, Yu
    Huang, Fen
    Wu, Xiuli
    Xuan, Li
    Wu, Meiqing
    BLOOD, 2011, 118 (21) : 1737 - 1738
  • [45] Immunosuppressive treatment of severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Zupan, IP
    Zver, S
    Pretnar, J
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (07) : 2931 - 2933
  • [46] Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Servais, Sophie
    Beguin, Yves
    Delens, Loic
    Ehx, Gregory
    Fransolet, Gilles
    Hannon, Muriel
    Willems, Evelyne
    Humblet-Baron, Stephanie
    Belle, Ludovic
    Baron, Frederic
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (08) : 957 - 972
  • [47] Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease
    Yanez, L.
    Insunza, A.
    Ibarrondo, P.
    de Miguel, C.
    Bermudez, A.
    Colorado, M.
    Lopez-Duarte, M.
    Richard, C.
    Conde, E.
    TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (05) : 761 - 767
  • [48] Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant
    Mirza, Sayeef
    Tandon, Ankita
    Jenneman, Dakota
    Cao, Shu
    Kumar, Ambuj
    Kidd, Michelle R.
    Khimani, Farhad
    Mishra, Asmita
    Liu, Hien D.
    Nishihori, Taiga
    Perez, Lia
    Bejanyan, Nelli
    Pidala, Joseph
    Nieder, Michael
    Elmariah, Hany
    BLOOD, 2019, 134
  • [49] Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Nassar, Amr
    Elgohary, Ghada
    Elhassan, Tusneem
    Nurgat, Zubeir
    Mohamed, Said Y.
    Aljurf, Mahmoud
    JOURNAL OF TRANSPLANTATION, 2014, 2014
  • [50] Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Chen, Yi-Bin
    Shah, Nirav N.
    Renteria, Anne S.
    Cutler, Corey
    Jansson, Johan
    Akbari, Mona
    Chen, Chunlin
    Quadri, Syed
    Parfionovas, Andrejus
    Devine, Steven M.
    BLOOD ADVANCES, 2019, 3 (23) : 4136 - 4146